cdk7 inhibitor
Showing 1 - 25 of >10,000
Malignant Female Reproductive System Tumor, Malignant Solid Tumor, Recurrent Malignant Female Reproductive System Tumor Trial
Not yet recruiting
- Malignant Female Reproductive System Neoplasm
- +3 more
- Biopsy
- +7 more
- (no location specified)
Nov 9, 2023
Breast Cancer Trial in Australia, Canada, New Zealand (Ipatasertib, Fulvestrant, Placebo)
Recruiting
- Breast Cancer
- Ipatasertib
- +2 more
-
Bowral, New South Wales, Australia
- +37 more
Aug 8, 2022
Advanced Breast Cancer Trial in Lebanon (Fulvestrant, Neratinib, Alpelisib)
Not yet recruiting
- Advanced Breast Cancer
- Fulvestrant
- +4 more
-
Lebanon, New HampshireDartmouth Hitchcock Medical Center
Jun 28, 2023
Neurofibromatosis 1 Trial run by the National Cancer Institute (NCI) (Abemaciclib)
Recruiting
- Neurofibromatosis 1
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 20, 2023
Prostate Cancer Trial in Canada (Palbociclib)
Active, not recruiting
- Prostate Cancer
-
Halifax, Nova Scotia, Canada
- +6 more
Jan 28, 2022
Breast Cancer Trial in Marseille (M1774, Fulvestrant injection)
Not yet recruiting
- Breast Cancer
- M1774
- Fulvestrant injection
-
Marseille, FranceInstitut Paoli Calmettes
Aug 9, 2023
Locally Advanced Breast Cancer, Hormone Receptor Positive,HER2-negative Breast Cancer Trial in Jinan (letrozole)
Recruiting
- Locally Advanced Breast Cancer
- Hormone Receptor Positiveļ¼HER2-negative Breast Cancer
-
Jinan, Shandong, ChinaBreast Cancer Center, Shandong Cancer Hospital and Institute
Apr 11, 2023
Breast Cancer Metastatic Cancer Trial in Shanghai (Fluzoparib, Dalpiciclib, Fulvestrant/AI)
Recruiting
- Breast Cancer Metastatic Cancer
- Fluzoparib
- +2 more
-
Shanghai, Shanghai, ChinaBreast cancer institute of Fudan University Cancer Hospital
Feb 26, 2023
Lung Cancer Squamous Cell, Solid Tumors, Head & Neck Cancer Trial in Boston (Palbociclib, Gedatolisib)
Recruiting
- Lung Cancer Squamous Cell
- +3 more
-
Boston, Massachusetts
- +2 more
Jan 9, 2023
Estrogen-receptor-positive Breast Cancer, HER2/Neu-Negative Breast Cancer, Advanced Breast Cancerv Trial in Chicago
Not yet recruiting
- Estrogen-receptor-positive Breast Cancer
- +3 more
- elacestrant, palbociclib, abemaciclib, ribociclib
-
Chicago, IllinoisNorthwestern University
Sep 25, 2023
Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed Trial in Hangzhou (dalpiciclib;
Recruiting
- Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed
- dalpiciclib; fluvestrant; compound gossypol acetate tablets
-
Hangzhou, Zhejiang, ChinazhejiangCH
Nov 9, 2023
Advanced HR+ HER2 Negative Breast Carcinoma Trial ((CDK)4/6 inhibitor)
Not yet recruiting
- Advanced HR+ HER2 Negative Breast Carcinoma
- (CDK)4/6 inhibitor
- (no location specified)
Sep 27, 2022
HR+ HER2- Men, Pre/Postmenopausal Advanced Breast Cancer Trial in Canada (Endocrine therapy may include one of the following
Active, not recruiting
- HR+ HER2- Men, Pre/Postmenopausal Advanced Breast Cancer
- Endocrine therapy may include one of the following therapies: letrozole, anastrozole, exemestane, tamoxifen or fulvestrant
- Endocrine therapy in combination with targeted therapy may include: everolimus plus exemestane or CDK4/6 inhibitor plus endocrine therapy
-
Calgary, Alberta, Canada
- +24 more
Sep 12, 2022
Breast Cancer Trial in Baltimore (Endocrine Therapy and a CDK 4/6 inhibitor)
Recruiting
- Breast Cancer
- Endocrine Therapy and a CDK 4/6 inhibitor
-
Baltimore, MarylandJohns Hopkins University
Jul 18, 2022
Breast Cancer Metastatic Cancer Trial in Shanghai (Apatinib, Dalpiciclib, Fulvestrant/AI)
Recruiting
- Breast Cancer Metastatic Cancer
- Apatinib
- +2 more
-
Shanghai, Shanghai, ChinaBreast cancer institute of Fudan University Cancer Hospital
Feb 26, 2023
Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Unresectable Solid Tumor Trial in United States (CDK Inhibitor
Active, not recruiting
- Advanced Malignant Solid Neoplasm
- +2 more
- CDK Inhibitor AT7519
- +3 more
-
Washington, District of Columbia
- +5 more
Oct 18, 2022
Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer Trial in Miami (AI+CDK4/6i, SERD+CDK4/6i, mTOR inhibitor +
Not yet recruiting
- Breast Cancer
- +3 more
- AI+CDK4/6i
- +7 more
-
Miami, FloridaUniversity of Miami
Apr 12, 2023
HR+ Metastatic Breast Cancer Patients Previously Treated With
Recruiting
- Breast Cancer
-
Beijing, Beijing, ChinaThe Fifth Medical Center of PLA General Hospital
Mar 3, 2022
Nasopharyngeal Carcinoma Trial in Guangzhou (Dalpiciclib Isetionate Tablets, Camrelizumab)
Recruiting
- Nasopharyngeal Carcinoma
- Dalpiciclib Isetionate Tablets, Camrelizumab
-
Guangzhou, Guangdong, ChinaDepartment of Nasopharyngeal Carcinoma, Sun Yat-sen University C
Feb 2, 2023
Advanced Breast Cancer Trial in Beijing (The combination of Dalpiciclib with physician-selected endocrine therapy, Chemotherapy
Recruiting
- Advanced Breast Cancer
- The combination of Dalpiciclib with physician-selected endocrine therapy
- Chemotherapy selected by the physician
-
Beijing, Beijing, ChinaPeking Union Medical College Hospital
May 22, 2023
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Trial (Giredestrant, Fulvestrant, Abemaciclib)
Not yet recruiting
- Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
- Giredestrant
- +6 more
- (no location specified)
Sep 26, 2023